- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 02.09. | TScan axes 75% of workforce to make room for solid tumor programs | ||
| 02.09. | SEC, FDA sign info-sharing agreement as a 'signal to the market' on insider trading | ||
| 02.09. | Novartis inks $3.2B subcutaneous drug delivery deal with Alteogen | ||
| 01.09. | Roche inks $1.53B deal for Simcere's B-cell-targeting antibody | ||
| 01.09. | ArsenalBio sheds most of staff in pivot to in vivo CAR-T | ||
| 01.09. | Alumis crushed by midstage lupus flop but plots path to phase 3 for TYK2 inhibitor | ||
| 01.09. | GSK catches phase 3 fever after mRNA flu vaccine beats standard shots | ||
| 31.08. | Electra aims to light up Nasdaq with IPO for phase 2/3 I&I push | ||
| 31.08. | ESC26: AstraZeneca's heart failure drug shows promise in ph. 2 trial | ||
| 31.08. | Eli Lilly inks $2.88B Merida buyout for autoimmune drugs against rogue antibodies | ||
| 28.08. | BioNTech-Genentech cancer vax records more deaths than control in scrapped ph. 2 test | ||
| 28.08. | AusperBio adds $120M series C to advance hep B oligo therapy through phase 3 and beyond | ||
| 28.08. | Teva saddles up as stalking horse bidder for bankrupt BioXcel's neuroscience portfolio | ||
| 28.08. | Genentech doubles down on ADC-resistant cancers with $1B DualityBio pact | ||
| 27.08. | CEPI backs push to bring Egyptian biotech's Ebola vaccine into clinic to curb fast-growing outbreak | ||
| 27.08. | Osivax bags flu vaccine rights to pursue combination shot vision | ||
| 26.08. | JATT mastermind launches latest biotech-focused SPAC via $60M IPO | ||
| 26.08. | Hansoh heralds China's move from 'follower' to 'frontrunner' in biopharma race | ||
| 26.08. | Spyre's rheumatoid arthritis plan toppled by subpar TL1A data | ||
| 26.08. | SK Biopharma pens $795M deal to usher Biohaven's epilepsy therapy towards hoped-for 2029 launch | ||
| 25.08. | Founded by Metsera backers, Sentivera emerges with $1.5B inflammatory disease deal | ||
| 25.08. | Capricor secures reprieve as FDA extends DMD cell therapy review | ||
| 24.08. | TME holds onto $1B dream for brain cancer drug as search for partners nears conclusion | ||
| 24.08. | Spruce's successful FDA talks plant seeds for Q4 filing of ultra-rare disease drug | ||
| 24.08. | Regenxbio gene therapy refiling plan derailed by FDA hold over spine MRI findings |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.